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Abstract
The use of multiparametric magnetic resonance imaging
(mp-MRI) for prostate cancer has increased over recent
years,mainly for detection, staging, and active surveillance.
However, suspicion of recurrence in the set of biochemical
failure is becoming a signiﬁcant reason for clinicians to re-
quest mp-MRI. Radiologists should be able to recognize
the normal post-treatment MRI ﬁndings. Fibrosis and
atrophic remnant seminal vesicles after prostatectomy are
often found and must be differentiated from local relapse.
Moreover, brachytherapy, external beam radiotherapy,
cryosurgery, and hormonal therapy tend to diffusely de-
crease the signal intensity of the peripheral zone on
T2-weighted images (T2WI) due to the loss of water con-
tent, consequently mimicking tumor and hemorrhage. The
combination of T2WI and functional studies like diffusion-
weighted imaging and dynamic contrast-enhanced im-
proves the identiﬁcation of local relapse. Tumor recurrence
tends to restrict on diffusion images and avidly enhances
after contrast administration either within or outside the
gland. The authors provide a pictorial review of the normal
ﬁndings and the signs of local tumor relapse after radical
prostatectomy, external beam radiotherapy, brachyther-
apy, cryosurgery, and hormonal therapy.
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Multiparametric magnetic resonance imaging (mp-MRI)
has been used for detection, localization, and staging of
prostate cancer (PCa) over the last few years. It combines
T1 and T2-weighted images (WI) with at least two
functional techniques such as dynamic contrast-en-
hanced MR imaging (DCE-MRI), diffusion-weighted
imaging (DWI), and MR spectroscopy (MRS) [1]. The
role of mp-MRI on PCa has, however, been extended to
cases of active surveillance, patients who refused biopsy,
MRI-guided or MRI-Ultrasound fusion biopsy, post-
treatment surveillance, and diagnosis of recurrence [1–4].
Radical prostatectomy (RP) and radiotherapy (RT),
either by external beam radiotherapy (EBRT) or
brachytherapy (BT), have curative intent in patients with
localized PCa. Other alternative treatment options like
cryosurgery and high-intensity focused ultrasound (HIFU)
are minimally invasive procedures with reduced toxicity.
However, they are not completely established yet [5].
This manuscript provides a pictorial review of the
normal ﬁndings and signs of local tumor relapse after RP,
EBRT, BT, cryosurgery, and hormonal therapy (HT).
Imaging approach to biochemical
failure
Recurrence after curative intent treatment is not
uncommon. Among patients undergoing RP or RT, 27%
to 53% develop biochemical failure (BF), which is de-
ﬁned as a rise in prostate-speciﬁc antigen (PSA) level,
and 16% to 35% need second-line treatment. PSA level
remains the basis of follow-up after curative treatment,Correspondence to: Joa˜oLopesDias; email: joaolopesdias85@gmail.com
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but the deﬁnition of BF differs between RP and RT.
After RP, it is deﬁned by two consecutive PSA values of
>0.2 ng/mL. After RT, with or without short-term
hormonal manipulation, it is deﬁned by a PSA increase
>2 ng/mL higher than the initial PSA nadir value. We
should emphasize that PSA recurrence tends to precede
clinical recurrence after RP or RT, in some cases by
several years [5–10].
PSA is also a good marker for following the course of
metastatic PCa, usually treated with HT. However, it
must be stressed that some poorly differentiated tumors
do not secrete PSA and laboratorial follow-up should
not constitute an isolated parameter in these patients.
Clinical progression, commonly with bone pain, should
also be considered [7].
After identifying a BF, it should be deﬁned whether
the recurrence has developed at local or distant sites.
Patients with local-only disease should be distinguished
and guided toward salvage local treatments. These
treatments are associated with considerable morbidity
and should be avoided in patients with distant metas-
tases, who have a lower chance of beneﬁting from them
and should undergo systemic therapies [8].
In the assessment of distant metastases, bone scans
for bone metastases and abdominopelvic computed
tomography (CT) for lymph node disease are usually
requested. Positron emission tomography with CT (PET/
CT) and diffusion-weighted whole-body MRI, both
more sensitive than bone scan and targeted radiographs
in the detection of bone metastases in patients with high-
risk PCa, may also be used [11–18]. According to the
European Society of Urogenital Radiology (ESUR) [1],
an MRI protocol based on T1WI and short tau inversion
recovery (STIR) sequences for axial and pelvic skeleton
is also recommended for bone metastasis assessment.
In local recurrence assessment, transrectal ultrasound
(TRUS) is neither sensitive nor speciﬁc in both post-RP
and RT cases. Due to its high contrast resolution, MRI
has been increasingly used in cases of suspicion of PCa
local relapse after RP or RT [19]. Conventional mor-
phological sequences may be untrustworthy and accu-
racy levels have increased with combined use of
functional techniques, namely DCE-MRI and DWI [7].
Radical prostatectomy
Radical prostatectomy implies removal of the entire
prostate gland and both seminal vesicles, along with
some of the fat surrounding tissue, with the goal of
getting negative margins. The procedure should be
accompanied by extended pelvic lymphadenectomy in
patients with intermediate- and high-risk PCa. In men
with low-risk PCa and<50% positive biopsy cores, both
the need and the extent of lymphadenectomy remain
controversial as the risk of lymph node involvement is
low [5, 20].
Radical retropubic prostatectomy (RRP) and per-
ineal prostatectomy are performed through open inci-
sions. Minimally invasive laparoscopic radical
prostatectomy (LRP) and robot-assisted laparoscopic
prostatectomy (RALP) have been recently developed and
are being increasingly used in many centers. RALP is
apparently associated with less blood loss and transfu-
sion need, when compared to RRP. Negligible differ-
ences regarding the remaining post-operative
complications were found [21, 22].
According to the European Association of Urology
(EAU) [5], RP is indicated in patients with low- and
intermediate-risk localized PCa (cT1a-T2b and Gleason
Score [GS] 2–7 and PSA < 20 ng/mL) and life ex-
pectancy higher than 10 years. Some selected patients
with low-volume, high-risk localized PCa (cT3a or GS
8–10 or PSA > 20 ng/mL) and very high-risk localized
PCa (cT3b-T4 N0 or any T N1) may also undergo RP,
but always in a multimodality setting. The goal of RP is
to eradicate the disease, conserving continence and po-
tency [23, 24].
Over the last decade, the diagnosis of PCa has been
established in younger men, so the preservation of sexual
function has gained greater importance. Nerve-sparing
RP may be attempted in patients with low risk for
extracapsular disease (T1c, GS < 7 and PSA < 10 ng/
mL). The recognition of neurovascular bundle involve-
ment on initial staging MRI is crucial [5, 25, 26].
A persistently elevated post-RP PSA level (6 weeks
after) is usually related to residual tumor, either due to
distant micrometastases or residual pelvic disease.
Rarely, a stable and low PSA level may be caused by
residual benign glands [8]. If PSA level increases
promptly after surgery, distant metastases are more
likely to be the cause. On the other hand, a later and
slower rise probably indicates local disease recurrence.
pT2-3a N0 tumors are more associated with local
recurrence, particularly when margins are negative, while
pT3b-4 and/or pN1 cancers are more likely to relapse at
distant sites. GS in the prostatectomy specimen also has
prognostic implications: when <8, local relapse is more
probable; when ‡8, systemic recurrence and cancer-
related death are more likely to happen [10, 27].
In the majority of centers, post-RP recurrent cancer is
deﬁned as two consecutive PSA values of 0.2 ng/mL or
more, despite some authors considering a higher cut-off
of 0.4 ng/mL [7, 8, 10, 28]. When a post-RP BF is rec-
ognized, salvage RT is generally performed without
histological confirmation of local relapse, since TRUS is
neither sensitive nor specific and a negative biopsy does
not rule out a local recurrence [7, 8]. MRI is very useful
in cases of suspicion of PCa local relapse after RP [19].
Several studies have been published over the last few
years reporting higher accuracy rates for the combined
use of morphological and functional sequences compar-
ing to morphological sequences alone. Cirillo et al. [29]
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showed that contrast-enhanced sequences improve
diagnostic performance when added to T2WI. In another
study, Sciarra et al. [30] reported a sensitivity of 87% and
specificity of 94% for the combined use of MRS and
DCE-MRI in the detection of local PCa recurrence in
patients with BF after RP.
After RP, bladder neck and vesicourethral anasto-
mosis (VUA) are expected to appear as a strongly hy-
pointense ring on T2WI, which reﬂects scar and ﬁbrotic
tissue (Figs. 1, 2), usually without or only with slightly
progressive enhancement on DCE images [8]. It is com-
mon to find a regular and circumferential enhancement
of the urethral wall under the bladder neck (Fig. 2). Both
high b values and the apparent diffusion coefficient
(ADC) map demonstrate low signal intensity due to
fibrosis. Bladder neck may appear dysmorphic in some
cases.
RP implies removal of the seminal vesicles. At their
site, T2WI typically shows linear hypointense ﬁbrosis
(Figs. 1, 2). If nodularity is found, functional techniques
should be assessed to exclude recurrence (Figs. 3, 4).
Absent or slight and late enhancement, as well as lack of
restriction on DWI, is unsuspicious signs. Retained
seminal vesicles may also preserve their high signal
intensity and convoluted structure on T2WI [8].
Local relapse after RP commonly appears in the
retrovesical space and at the VUA. On T2WI, it is usu-
ally seen as an interruption of the normal hypointense
ring of the bladder neck and VUA by a tumor with
higher signal intensity (Figs. 5, 6, 7, 8) [31]. On DCE
images, recurrence typically presents as early enhancing
nodules (Figs. 5, 6, 7, 8, 9, 10). Some authors like Cas-
ciani et al. [32] have reported the utility of time-signal
intensity curves. However, this feature is not consensual
in the set of recurrence suspicion. Recurrence may also
be seen as bright foci on DWI at high b values (Figs. 6, 9,
10), but this evaluation may be hampered due to lack of
anatomical references, which may, however, be overcome
using T2WI-DWI fusion images. Bone recurrence usually
demonstrates the same functional behavior, presenting as
enhancing nodules on DCE images (Fig. 11) and
restrictive lesions on DWI.
External beam radiotherapy
External beam radiotherapy (EBRT) remains a valid
alternative to surgery for curative therapy. It is recom-
mended for localized PCa (T1c-T2c N0 M0), even in
young patients who reject surgical intervention. In high-
risk patients with locally advanced PCa (T3-4 N0 M0),
long-term androgen deprivation therapy (ADT) before
and during RT is recommended and leads to increased
overall survival. EBRT may also be used after RP in T3
N0 M0 tumors, improving biochemical and clinical dis-
ease-free survival. This combination is particularly
effective in cases with post-surgical positive margins. In
very high-risk prostate cancer (c-pN1 M0), RT alone is
inadequate. These patients, if no severe comorbidity is
found, should undergo EBRT and immediate long-term
adjuvant hormonal treatment [5, 33].
The current deﬁnition of BF after radiation is a PSA
rise of more than 2 ng/mL above the post-treatment
nadir [10]. In contrast to post-RP local relapse, it is
necessary to obtain histological confirmation of the local
recurrence after radiation therapy, taking into account
the high morbidity of salvage options [8].
Fig. 1. Axial and sagittal T2 WI show normal post-prostatectomy fibrosis at the level of seminal vesicles (A) and typical
hypointense bladder neck and peri-urethral tissue (B).
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After EBRT, the prostate gland loses normal zonal
anatomy due to diffuse low signal intensity of the
peripheral zone on T2WI (Figs. 12, 13, 14). This dimin-
ishes the contrast between tumor and irradiated tissue,
hampering recurrence detection on morphological se-
quences [8].
Fibrosis and changes of parenchymal vascularization
after RT modify the biological behavior of tumors and
normal tissue, and may consequently limit the use of
functional techniques like DCE-MRI or DWI. Even
though, some manuscripts with promising results have
been published. According to a study of Haider et al.
[34], DCE-MRI performs better than T2WI in the
detection of tumor relapse in the peripheral zone after
EBRT. The authors reported sensitivity and specificity
levels of 72% and 85%, respectively. The enhancement of
post-radiation fibrosis is low and slowly progressive,
whereas recurrent cancer is typically hypervascular [8].
Kim et al. [35] concluded that the use of combined T2WI
and DWI demonstrates better diagnostic performance
when compared to T2WI alone for predicting locally
recurrent PCa after radiation therapy. In another study,
Morgan et al. [36] also emphasized the added vale of
DWI, concluding that ADC measurement is useful for
detecting local tumor relapse larger than 0.4 cm2 within
the prostate. In a more recent study, Donati et al. [37]
Fig. 2. Axial (A, B) and coronal (C) T2WI show normal post-
prostatectomy fibrosis at the level of seminal vesicles (A) and
typical appearance of the bladder neck (B, C). It usually
presents as a strongly hypointense ring with variable thick-
ness. DCE subtracted image at a lower axial plane (D) shows
the normal ring enhancement of the urethra (arrow), with no
enhancement of the surrounding fibrotic tissue.
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concluded that the combination of T2WI and DWI
achieves the best overall diagnostic accuracy and the
highest inter-reader agreement in the detection of recur-
rent PCa after RT. In other studies, Arumainayagam
et al. [38] and Akin et al. [39] demonstrated that mp-MRI
using T2WI, DCE-MRI, and DWI is an accurate test for
detecting radio-recurrent PCa. The former achieved
accuracy levels of 80%–90%.
Some studies were also developed regarding the utility
of MRS. Pucar et al. [40] showed that MRS might be
more sensitive than TRUS and digital rectal examination
for localization of post-EBRT cancer recurrence.
Transperineal brachytherapy
Transperineal BT is a secure and effective treatment for
low-risk PCa. According to the EAU, it is recommended
in patients with cT1-T2a N0 M0, GS < 7 (or 3 + 4),
PSA £ 10 ng/mL, £50% of biopsy cores involved with
cancer, prostate volume <50 mL, without a previous
transurethral resection of the prostate (TURP), and an
International Prostatic Symptom Score £12 [5, 21].
This transperineal technique is performed with
TRUS. The patient is positioned in a dorsal decubitus
gynecological position and seeds’ implantation is per-
formed under general anesthesia or spinal block [41].
There is no consensus on BF after BT. A PSA
bounce, deﬁned as a temporary increase of the PSA level
followed by a further decrease, occurs in 30%–60% of
patients 12–24 months after implantation, without clin-
ical relevance. PSA bounce typically persists for about
12 months and PSA levels usually do not increase more
than 1.0 ng/mL [8].
BT may produce several levels of magnetic suscepti-
bility artifacts on both morphological and functional
sequences (Fig. 15), hampering cancer detection. When
visible, BT seeds appear as dark dots on T2WI and ADC
map. Similarly to EBRT, post-BT prostate tends to ap-
pear diffusely hypointense on T2WI, with loss of the
normal zonal anatomy (Fig. 16). BT seeds are often seen
outside the gland, in the surrounding fat planes and less
commonly at the base of the penis. According to Rou-
vie`re et al. [8], recurrent foci may be identified on DCE
images as early-enhanced nodules. The use of DWI is not
well established in the detection of intraglandular
recurrence after BT mainly due to local artifacts, but it
remains useful in the setting of locally aggressive relapse
and bone metastases (Fig. 17, 18).
Cryosurgery
In cryosurgery, freezing of the prostate gland is guar-
anteed by the placement of cryoneedles under TRUS
guidance, thermosensors at the level of the external
sphincter and bladder neck, and insertion of a urethral
warmer. A -40C temperature is achieved in the mid-
gland and at the neurovascular bundle, generally after
two freeze–thaw cycles, inducing cell death. Cellular
dehydration, rupture of cellular membranes, vascular
stasis, and microthrombi are the underlying mechanisms
[42–45].
Potential candidates for cryosurgery are those with
low- or intermediate-risk PCa and comorbidities that
contraindicate RT or RP. At the time of therapy, pros-
tate gland should be <40 mL, so prior hormonal
downsize may be needed [43, 44].
Fig. 3. Axial T2W images show normal post-prostatectomy fibrosis at the level of seminal vesicles and remnant right seminal
vesicle (A). The distal segment of the vas deferens may be also seen (B).
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There are no validated criteria for BF after
cryotherapy. Some centers consider a PSA cut-off of
around 1 ng/mL, which may be combined with a post-
treatment biopsy [8, 42, 43].
Data in literature are scarce regarding both normal
ﬁndings and PCa recurrence after cryosurgery. Similar to
EBRT and BT, it is expected to ﬁnd diffuse hyposignal
within the peripheral zone on T2WI (Fig. 19). Some
studies like that of Parivar et al. [46] concluded that
MRS is superior to TRUS and MRI in detecting recur-
rence after cryosurgery. To the best of our knowledge,
DCE-MRI and DWI have not been widely studied.
Hormonal therapy
Prostate cells undergo apoptosis when deprived of
androgenic stimulation. Testosterone is crucial for
growth and perpetuation of tumor cells, so androgen
deprivation therapy (ADT) constitutes one of the ther-
apeutic options for PCa. ADT aims to suppress the
secretion of testicular androgens (castration) or inhibit
the action of circulating androgens at the receptor level
(anti-androgens) [10, 47].
Hormonal therapy (HT) is the standard option in
metastatic PCa, becoming mandatory if patients are
Fig. 4. Status post-RP in a patient with no laboratorial or
imaging signs of recurrence. Axial T2WI A shows an elon-
gated, strongly hypointese, thick fibrotic nodularity at the site
of the left seminal vesicle. This area demonstrates very low
signal intensity on the ADC map (B, red contour) and at high b
values (not shown), as well as no significant enhancement on
DCE images (C).
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symptomatic. In N + M0, HT also constitutes the
standard treatment after extended node dissection
if more than 2 positive nodes are found. Symptomatic
patients with extensive T3–T4 and high PSA level
(>25–50 ng/mL) may also beneﬁt with HT, but not as
monotherapy, unless patients are unﬁt for RT. The
use of HT in T1a–T2c localized PCa is limited and
only indicated in symptomatic patients who need
symptom palliation or are unﬁt for curative treatment
[10].
Many patients undergoing HT were initially diag-
nosed with either metastatic or locally advanced cancer.
In these cases, BF is frequently associated with fast
symptomatic progression [48, 49]. Even under HT, it is
common to find large tumors with extracapsular exten-
sion or invasion of the seminal vesicles on T2WI. Follow-
up examinations may show changes in functional se-
quences, namely increasing ADC value and different
dynamic post-gadolinium patterns. However, more
studies are needed to validate these findings. HT may
also decrease prostatic volume and hamper zonal anat-
omy depiction on T2WI by decreasing peripheral signal
intensity, especially when combined with EBRT or BT
(Fig. 20, 21).
Fig. 5. Images in a 65-year-old man after RP. This patient
had a PCa (GS 7 and initial PSA of 12.6 ng/mL). BF was
detected 6 years after RP (PSA 1.3 ng/mL). Axial T2WI (A)
shows interruption of the normal signal hypointensity of the
vesicourethral junction by a right posterior tumor with mod-
erate signal intensity (arrow). This area demonstrates great
enhancement on DCE images (subtracted axial image, B;
sagittal reconstruction, C).
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Fig. 6. Images in a 72-year-old man after RP due to PCa
(GS 7). 4 years after surgery, BF was detected (PSA 16.2 ng/
mL) and HT was initiated. Axial (A) and sagittal (B) T2WI
show local recurrence, seen as a moderately intense nodule
located posteriorly to the vesicourethral junction (arrows).
This nodule is bright on DWI at b 1200 (C), dark on the ADC
map (D), and enhances on DCE images (E).
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Fig. 7. Images in a 63-year-old man after RP. This patient
had a PCa (GS 7, pT2c Nx, with negative margins). 10 years
after surgery, BF was detected (PSA 9.8 ng/mL). Axial (A)
and sagittal (B) T2WI show interruption of the vesicourethral
junction hypointensity ring by an anterior, slightly hyperin-
tense nodule (arrows). This nodule enhances on DCE images
(C) and shows type 2 dynamic curve (D).
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Fig. 8. Images in a 68-year-old man after RP due to PCa
(GS 6). 15 years after surgery, BF was detected (PSA
0.80 ng/mL). Coronal (A) and axial (B) T2WI show a dimor-
phic bladder neck and a poorly defined right posterior area
with moderate signal intensity (arrows). Partial volume arti-
facts hamper morphologic evaluation, but DCE images (C)
reveals suspicious enhancement. Posteriorly to the bladder
neck, normal ring enhancement of the rectal mucosa is also
seen.
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Fig. 9. Images in a 70-year-old man after RP and ilio-obtu-
rator lymphadenectomy. This patient had a PCa (GS 7, pT3c
N1, with positive margins). 10 years after surgery, BF was
detected under HT (PSA 6.4 ng/mL). Axial T2WI (A) shows a
nodular, hypointense thickening of the bladder base (arrow),
highly restrictive on DWI (B), hypointense on the ADC map
(C), and strongly enhancing on T1WI FS after gadolinium
administration (D). A left lombo-aortic lymph node metastasis
is also seen on T1WI (E, arrow).
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Fig. 10. Images in a 67-year-old man after RP due to PCa
(GS 8). 5 years after surgery, BF was detected (PSA 0.90 ng/
mL). Axial T2WI (A) shows a small tumor deposit with inter-
mediate signal at the site of the right seminal vesicle. This
relapse focus enhances on DCE images (B) and demon-
strates high signal intensity on DWI at b 1200 (C).
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Fig. 11. Images in a 69-year-old man after RP. This patient
had a PCa (GS 7). 6 years after surgery, BF was detected
(PSA 1.90 ng/mL). Axial T1WI (A) shows a small, hy-
pointense bone metastasis in the right sacral wing. DCE im-
age (B) shows early enhancement. No local relapse was
found in the prostatectomy bed.
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Fig. 12. Images in a 63-year-old man who underwent EBRT
and HT due to a PCa (GS 8, with extracapsular extension).
5 years after starting treatment, PSA decreased from 12 to
0.25 ng/mL. Axial (A, B) and sagittal (C) T2WI show diffuse
signal hypointensity of the prostate gland and seminal vesi-
cles (arrow), stranding of the surrounding fat planes, as well
as diffuse thickening of the bladder and rectum walls, owing to
radiation-induced cystitis and proctitis, respectively.
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Fig. 13. Images in a 59-year-old man after EBRT and HT for
PCa (GS 6 and initial PSA of 12.79 ng/mL). 5 years later,
PSA slightly increased from the immediate post-RT nadir to
1.42 ng/mL. mp-MRI and TRUS-guided biopsy were both
negative for local recurrence. Axial T2WI (A) shows a dif-
fusely hypointense gland, with loss of the normal
zonal anatomy. DCE images (B) show non-specific
diffuse central enhancement. Images at b 1200 (C) show no
significant restriction, with corresponding hypersignal on the
ADC map (D). This is a non-suspicious shine-through effect.
2828 J. Lopes Dias et al.: Post-treated prostate cancer
Fig. 14. Images in a 72-year-old man who underwent EBRT
and complete hormonal blockage due to PCa (GS 9 and initial
PSA of 33 ng/mL). 3 years after EBRT, a significant BF was
detected (PSA 19.1 ng/mL) under HT. Axial T2WI (A) shows
a small, diffusely hypointense prostate. At the right side, an
area of more pronounced hypointensity is found (red arrow),
showing no restriction on DWI (B) and strong hyposignal on
the ADC map (C), probably related to fibrotic tissue. However,
a round, right inguinal node metastasis is seen, highly
restrictive on DWI and dark on the ADC map (white arrows).
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Fig. 15. Status post-BT. Axial T2WI shows exuberant arti-
facts that hamper prostatic parenchyma evaluation.
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Fig. 16. Images in a 66-year-old man who underwent BT
due to PCa (GS 7). PSA decreased from 5.63 to 1.97 ng/mL
1 month after treatment. 2 years later, BF was diagnosed
(PSA 13.65 ng/mL). Axial T2WI (A) shows a diffusely hy-
pointense peripheral zone, with some dark spots corre-
sponding to BT seeds, also seen on the ADC map (B). DCE
images (C) show non-specific central enhancement. Axial
T1WI (D) and T2WI FS (E) demonstrate a left internal iliac
node metastasis and a left iliac bone metastasis, respectively
(arrows).
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Fig. 17. Images in a 50-year-old man after BT due to a PCa
(GS 7). 10 years after, BF was detected (PSA 6.2 ng/mL).
Axial (A) and sagittal (B) T2WI show an exuberant local
recurrence, seen as a huge tumor with extracapsular exten-
sion (red arrow) and invasion of the seminal vesicles and
rectum (white arrow). Local tumor relapse shows strong
restriction on DWI at b 1200 (C) and slightly peripheral
enhancement on DCE images (D), probably due to necrosis.
Bilateral, inguinal node metastases are also seen on both
DWI and DCE images (arrows).
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Fig. 18. Images in a 61-year-old man after BT. This patient
had a PCa (GS 6) and a BF was detected 6 years after
treatment (PSA 2.4 ng/mL). Axial T1WI (A) and T2WI (B)
show a pathologic fracture in the posterior column of the left
acetabulum, associated with a soft tissue component and
cortical disruption (arrows). Edema of the surrounding mus-
cles and acetabulum is seen on T2WI FS (C). Soft tissue
component is, respectively, dark and bright on the ADC map
(D) and DWI, denoting restriction (E).
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Fig. 19. Images in a 72-year-old man who underwent
cryotherapy due to PCa (GS 7). 6 years later, BF was de-
tected (PSA 1.27 ng/mL) and patient started HT. Rectal gas
artifacts impair axial T2WI (A) reading, but a hypointense
nodule may be seen close to the left seminal vesicle (arrow).
Coronal T2WI (B) shows a small, diffusely hypointense gland.
DCE images (C) better depicts local recurrence, showing
three enhanced nodules.
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Fig. 20. Images in a 61-year-old man. This patient had a
PCa (GS 7 and a initial PSA of 9.5 ng/mL) and refused EBRT
or RP. HT was started. After 10 years, PSA was 1.38 ng/mL
and the patient remained asymptomatic. Axial T2WI (A, B)
show a small prostate, with conserved zonal anatomy. In the
left apex, a hypointense lesion is found (arrow), with corre-
sponding non-suspicious high signal on the ADC map (C).
This lesion demonstrates progressive enhancement on DCE
images (D), with type 1 curve (E), probably corresponding to a
focal area of inflammation. No local tumor progression was
found.
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Fig. 21. Images in a 66-year-old man. This patient had a
PCa (GS 7 and a initial PSA of 22 ng/mL). HT was started and
after 10 months PSA was 0.55 ng/mL. HT was then inter-
rupted and the patient remained asymptomatic. 1 year later,
PSA increased to 9.68 ng/mL. Axial T2WI (A) shows a dif-
fusely hypointense, small prostate, with left spiculated contour
suggesting extracapsular extension. DCE images (B)
demonstrate avid enhancement involving both left central and
peripheral gland. Axial T2WI (C) also shows bilateral, external
iliac lymph node metastases (arrows). A right perianal ab-
scess is also depicted (red arrow).
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Conclusion
Once a post-treatment BF is detected, local or distant
recurrence should be recognized. Several studies have
already demonstrated the value of mp-MRI in the
detection of post-RP and EBRT tumor relapse. The
combination of morphological sequences with functional
techniques like DCE-MRI and DWI has improved
diagnostic accuracy levels and is now widely accepted
and used.
Susceptibility magnetic artifacts after BT appear to
signiﬁcantly hamper tumor foci detection within the
gland. However, in some non-artifact-hampered exams,
mp-MRI might be useful to distinguish between clinically
irrelevant PSA bounce and true BF. This issue remains
controversial and surely implies further research. More-
over, other studies are also needed to validate the use of
mp-MRI in the detection of recurrent PCa after less
widespread therapies, like cryosurgery or HIFU.
Even in the assessment of distant metastases, MRI
may be used. Despite bone scans and abdominopelvic
CT being typically the ﬁrst choices, both bone and lymph
node metastases may be identiﬁed on MRI. Particularly
in high-risk patients, an MRI protocol including T1WI
and STIR sequences is already set as an alternative to
bone scans.
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